Release Date: 19/05/11 16:02 Summary: Moss Cross Claim Price Sensitive: Yes Download Document 31.34KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%